| Sodium Bicarbonate | |||
|
|
Search by color, shape and markings. click here
|
|
Check any 2 drugs for interactions. click here
|
|
|
Compare any two drugs side by side. click here
|
|
|
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
|
Treatment of metabolic acidosis associated with many conditions including severe renal disease (e.g., renal tubular acidosis), uncontrolled diabetes (ketoacidosis), extracorporeal circulation of the blood, cardiac arrest, circulatory insufficiency caused by shock or severe dehydration, ureterosigmoidostomy, lactic acidosis, alcoholic ketoacidosis, use of carbonic anhydrase inhibitors, and ammonium chloride administration.
Generally considered the alkalinizing agent of choice for oral or parenteral therapy.
Specific role of sodium bicarbonate therapy in the treatment of diabetic ketoacidosis not established. Administration is generally reserved for the treatment of severe acidosis (e.g., arterial pH less than 7–7.15 or serum bicarbonate concentration of 8 mEq/L or less) because of the potential risks of sodium bicarbonate therapy in the treatment of this disorder.
The Guidelines on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care state that IV sodium bicarbonate is not recommended for routine use in ACLS. May be useful in some resuscitation situations (e.g., preexisting metabolic acidosis, hyperkalemia, tricyclic antidepressant overdosage, sodium-channel blocking agent toxicity, prolonged cardiac arrest).
Treatment of hemolytic reactions requiring alkalinization of the urine to diminish the nephrotoxic effects of blood pigments; also to increase urinary pH in order to increase the solubility of certain weak acids (e.g., cystine, sulfonamides, uric acid).
Administer orally, by direct IV injection or infusion.
May be administered by intraosseous injection† in pediatric patients without reliable/immediate IV access undergoing cardiopulmonary resuscitation.
Also administered by subcutaneous injection if diluted to isotonicity (1.5% sodium bicarbonate solution); avoid extravasation of hypertonic sodium bicarbonate injections.
Administered orally in the treatment of mild to moderately severe acidosis, in conditions (e.g., chronic renal failure) requiring prolonged therapy with an alkalinizing agent, and in conditions in which IV administration of the drug is not necessary (e.g., alkalinization of the urine).
Neonates and children <2 years of age: Administer hypertonic sodium bicarbonate injections by slow IV infusion of a 4.2% solution (up to 8 mEq/kg daily).
Each 84 mg or 1 g of sodium bicarbonate contains 1 or about 12 mEq, respectively, each of sodium and bicarbonate ions.
Older children: 2–5 mEq/kg as an infusion over 4–8 hours in less urgent forms of metabolic acidosis. Subsequent doses should be determined by the response of the patient and appropriate laboratory determinations.
Plan sodium bicarbonate therapy in a stepwise manner, since the degree of response following a given dose is not always predictable. Reduce dose and frequency of administration after severe symptoms have improved.
Infants and children: Initially, 1 mEq/kg (1 mL/kg of an 8.4% sodium bicarbonate solution).
Drug-induced cardiovascular emergencies (tricyclic antidepressant or other sodium-channel blocking agent toxicity): 1–2 mEq/kg by direct IV injection until the arterial pH >7.45, then infuse 150 mEq/L in 5% dextrose injection to maintain alkalosis; in severe intoxication, the pH has been increased to 7.5–7.55.
Ventricular arrhythmias associated with cocaine toxicity: 1–2 mEq/kg.
Infants and children: Initially, 1 mEq/kg (1 mL/kg of an 8.4% sodium bicarbonate solution).†
1–10 mEq (84–840 mg) per kg daily, adjusted according to response.
Initially, administer no more than 33–50% of the calculated bicarbonate requirements when initial, rapid administration of the drug is considered necessary. Consult specialized references on fluid and electrolyte and acid-base balance for specific recommendations.
2–5 mEq/kg dose as an infusion over 4–8 hours in less urgent forms of metabolic acidosis. Subsequent doses should be determined by the response of the patient and appropriate laboratory determinations. Therapy should be planned in a stepwise manner, since the degree of response following a given dose is not always predictable. Generally, the dose and frequency of administration should be reduced after severe symptoms have improved.
Partially correct acidosis, generally to an arterial pH of about 7.2, in order to avoid rebound alkalosis.
Initially, 1 mEq/kg.
Drug-induced cardiovascular emergencies (tricyclic antidepressant or sodium-channel blocking agent [e.g., procainamide, flecainide] toxicity): 1–2 mEq/kg by repeated direct IV injections to maintain an arterial pH of 7.45–7.55. Maintenance infusion of 150 mEq/L plus 30 mEq of potassium chloride per liter in 5% dextrose injection recommended. For acute decompensation, may administer sodium bicarbonate direct IV injections without determining serum pH, if QRS interval >100 msec or hypotension develops.
Initially, 20–36 mEq daily, given in divided doses when plasma bicarbonate concentration is less than 15 mEq/L. Titrate dosage to provide a plasma bicarbonate concentration of about 18–20 mEq/L. To relieve symptoms and prevent or stabilize renal failure and osteomalacia in patients with renal tubular acidosis, higher dosages of sodium bicarbonate are necessary.
Distal (type 1) renal tubular acidosis: Initially, 0.5–2 mEq/kg daily, given in 4 or 5 divided doses. Titrate dosage until hypercalciuria and acidosis are controlled, and according to the response and tolerance of the patient. Alternatively, 48–72 mEq (about 4–6 g) daily.
Proximal (type 2) renal tubular acidosis: 4–10 mEq/kg daily, given in divided doses.
Initially, 48 mEq (4 g), followed by 12–24 mEq (1–2 g) every 4 hours. Dosages of 30–48 mEq (2.5–4 g) every 4 hours, up to 192 mEq (16 g) daily, may be required in some patients. Titrate dosage to maintain the desired urinary pH.
Related Learning Centers |